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Little is known about the epidemiology of MDS in minority populations. The IPSS and newly released IPSS-R are
important clinical tools in prognostication of patients with MDS. Therefore, we conducted a retrospective
epidemiological analysis of MDS in an ethnically diverse cohort of patients. Demographics, disease characteristics,
and survival were determined in 161 patients seen at Montefiore Medical Center from 1997 to 2011. We observed
that Hispanics presented at a younger age than blacks and whites (68 vs. 73.7 vs. 75.6 years); this difference was
significant (p = 0.01). A trend towards greater prevalence of thrombocytopenia in Hispanics was observed, but this
was not significant (p = 0.08). No other differences between the groups were observed. Overall median survival after
diagnosis was the highest among Hispanics (8.6 years) followed by blacks (6.2 years) and Caucasians (3.7). Adjusted
hazard ratios however did not show significant differences in risk of death between the groups. The IPSS-R showed
slightly better discrimination when compared to the IPSS in this cohort (Somers Dxy 0.39 vs. 0.35, respectively) but
observed survival more was more closely approximated by IPSS than by IPSS-R. Our study highlights the possibility
of ethnic differences in the presentation of MDS and raises questions regarding which prognostic system is more
predictive in this population.
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The myelodysplastic syndromes (MDS) are a diverse
group of hematological diseases characterized by dyspla-
sia of myeloid lineage cells, peripheral cytopenias, and
an increased risk of evolution to acute myeloid leukemia
(AML) [1]. Prognosis is highly variable, and a number of
scoring systems exist to risk stratify patients and guide
decisions on treatment [2-5].
The impact of race on MDS is poorly understood [6].
In the United States, Surveillance Epidemiology and End
Results (SEER) data suggests that MDS is more common
in whites than in blacks, but survival is equal [7,8].
Retrospective data from the University of Maryland Can-
cer Center showed slower rates of referral among blacks
with MDS versus whites to tertiary care centers, suggest-
ing that there are racial disparities in the care of MDS
[9]. Interestingly, this disparity did not lead to differ-
ences in outcomes. In a multicenter retrospective trial* Correspondence: amit.verma@einstein.yu.edu
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in finding good matches for the black patients rather than
inherent characteristics of the disease [10]. A comparison
of a cohort of German patients with Japanese patients
showed significant differences in incidences of French-
American-British (FAB) classifications of MDS; Japanese
patients had higher rates of myelodysplastic syndrome
unclassified (MDS-U) with pancytopenia and refractory
cytopenia with unilineage dysplasia (RCUD) [11,12]. In
addition, the Japanese patients had longer overall survival
and leukemia free survival compared with the German
patients. This study further showed that pathologists in
Germany and Japan interpreted the same samples in simi-
lar fashions, showing these differences were not due to
varying interpretations. A reported cohort from Brazil
showed that women comprised a greater percentage of
cases than men, a finding contrary to most other countries
[13]. The authors suspect that this is because womenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sridharan et al. Experimental Hematology & Oncology 2014, 3:22 Page 2 of 6
http://www.ehoonline.org/content/3/1/22handle more of the pesticide in that country, implicating
environmental factors as a reason for international
variability. Furthermore, MDS seems to be diagnosed
at different ages in different countries; the results of
two studies on small cohorts of patients shows that
the median age of diagnosis in Korea, Japan, and German
were 57 years, 60 years, and 74 years, respectively [14].
A variety of prognostic systems exist to risk stratify
patients with MDS. The Myelodysplastic Syndrome
International Prognostic Scoring System (IPSS) has been
widely used since being introduced in 1997 [3]. It strati-
fied patients into different risk categories based on per-
centage of bone marrow blasts, number of peripheral
cytopenias, and karyotype and has been used to guide
management decisions. In 2012, the IPSS was revised
(IPSS-R) [4]. The IPSS-R increased the number of risk
categories, expanded the number of cytogenetic abnor-
malities used, and changed the way scores were com-
puted. Compared to the IPSS, the IPSS-R showed good
prediction in a larger cohort of patients. The ethnicity
breakdown of the overall cohort has not been published
or widely circulated.
Despite the increased awareness of racial and geo-
graphic differences in the morphology and prognosis of
MDS, little data exists which compares the characteris-
tics of MDS in Hispanics with those of blacks and whites
who live in the same geographic area. We conducted a
retrospective chart review of patients diagnosed with
MDS at a single center, diverse, urban medical center to
determine if differences in presentation existed between
the three racial groups. Furthermore, we risk stratified
all patients according to the IPSS and the IPSS-R to
determine if these scores accurately predicted prognosis
in our racially diverse cohort.
Materials and methods
We retrospectively analyzed the charts of all patients
diagnosed with MDS at a single center (Montefiore
Medical Center) in the Bronx, New York between the
years of 1997 and 2011. Using the Clinical Looking Glass
software, we identified all patients who presented to an as-
sociated hospital or outpatient clinic with an International
Classification of Diseases, Book 9 (ICD-9) diagnosis or
related diagnosis of MDS. Individual codes used were
238.72, 238.73, 238.74, and 238.75, which correspond with
diagnoses of “Low grade MDS lesions,” “High grade MDS
lesions, “MDS with 5Q deletion,” and “MDS, unspecified,”
respectively. Clinical Looking Glass is a software tool
which allows for the collection and analysis of patient data
(e.g., demographic and laboratory data) for all visits to our
institution between the years of 1997 and the present.
Patient records containing an ICD-9 diagnosis code for
MDS were further examined for bone marrow biopsy re-
sults; only patients’ bone marrow biopsy results consistentwith MDS by World Health Organization (WHO) criteria
were included into the study. Patients with treatment-
related MDS were not excluded.
Demographic information (age, sex, and ethnicity) was
obtained from the medical record. Information regarding
ethnicity was collected through patient self-report ques-
tionnaires. Ethnic categories were “White”, “Black”,
“Hispanic”, “Other”, and “Unknown”. Hispanics could be
of any race. Few patients reported “Other” (n = 1) and
“Unknown” (n = 2) race/ethnicity and we did not include
them in our analyses.
Laboratory data (peripheral blood counts and bone
marrows biopsy results including cytogenetic findings)
were also recorded from the medical record. Anemia
was defined as hemoglobin < 10 g/dL, thrombocytopenia
as < 100,000 platelets per microliter, and neutropenia as
< 1,800 neutrophils per microliter. Cytogenetics were
determined by metaphase cytogenetics and fluorescent
in-situ hybridization (FISH) with a panel of DNA probes
for clinically relevant derangements. Probes for 5q31,
monosomy 5, monosomy 7, deletion 7q31, trisomy 8,
TP53, and deletion 20q12 were routinely checked for by
FISH. For each patient, IPSS and IPSS-R risk category
were calculated according to published methods [3,4].
We defined the date of MDS diagnosis as the date of
the first bone marrow biopsy consistent with MDS in
our record. To determine the date of death, we exam-
ined the medical record and the Social Security Death
Index. If the patient died at our institution, we recorded
the date of death from the medical record. For patients
without a date of death in the medical record, we quer-
ied the Social Security Death Index. If no date of death
was found in the Social Security Death Index query, we
censored the patient on the day the query was performed.
The study protocol was approved by the Montefiore
Medical Center Institutional Review Board.
Statistical analysis
To compare differences in baseline presenting character-
istics between Black, White, and Hispanic patients with
MDS, we compared continuous variables (e.g., age) using
the Kruskall-Wallis test and categorical variables (e.g.,
race/ethnicity, presence of peripheral cytopenias, IPSS
and IPSS-R risk group) using the chi-square or Fisher
exact test, where appropriate. No adjustments for mul-
tiple testing were applied.
Next, to examine survival of Black, White, and Hispanic
patients with MDS, we constructed Kaplan-Meier curves
and compared unadjusted survival using the log-rank test.
Then, we compared survival between Black, White, and
Hispanic patients with MDS after adjusting for demo-
graphics and IPSS/IPSS-R risk group using multivariable
Cox proportional hazards regression models. We devel-
oped three separate multivariable models: 1) adjusting for
Table 1 Demographic characteristics at diagnosis for all











Median (IQR) 72.5 (14.9) 73.7 (16.1) 68.0 (21.7) 75.6 (14.0) 0.01
Sex, n (%)
Female 81 (50.3) 29 (53.7) 28 (57.1) 24 (41.4) 0.22
n = number of patients, IQR = interquartile range.
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and 3) adjusting for age, sex, and IPSS-R. In each model,
we verified the proportionality assumption for all inde-
pendent variables.
Finally, we examined the performance of the IPSS and
IPSS-R in our cohort of patients. To assess discrimin-
ation, the ability of the IPSS or IPSS-R score to distin-
guish between high risk and low risk, we calculated
Somers’ Dxy for right-censored survival data [15]. To as-
sess calibration, the degree to which the observed sur-
vival in our cohort was similar to the survival predicted
by IPSS or IPSS-R, we constructed graphs of observed
versus predicted survival. Statistical analyses were per-
formed with SAS 9.3 (SAS Institute, Cary, NC, USA)
and R 3.0 (R Foundation for Statistical Computing,
Vienna, Austria); a two-tailed P-value ≤ 0.05 was consid-
ered significant.
Results
A total of 543 patients were identified who visited Mon-
tefiore outpatient or inpatient facilities with an ICD-9
diagnosis of MDS between the years of 1997 to 2011
(Figure 1). Of these patients, 173 had bone marrow bi-
opsies that were consistent with MDS and were included
in the analysis. The remaining patients either did not
have bone marrow biopsies in our system, had bone
marrow biopsies that were normal, or had diagnoses
consistent with other hematological disorders (including
lymphoma, multiple myeloma, de novo acute myeloid
leukemia, etc.). Complete demographic and laboratory
data were available for 161 of these patients. Results ofFigure 1 Summary of patients included in analysis. ICD-9 =
International Classification of Diseases, Book 9, IPSS-R = Revised
international prognostic scoring system, IPSS = International prognostic
scoring system.cytogenetic studies were available in 84% (135/161) of
patients, which allowed computation of IPSS and IPSS-R
risk categories.Analysis of patients with complete demographic and
laboratory data
Of patients with complete demographic and laboratory
data (n = 161), the median age was 72.5 (IQR: 14.9) with
50.3% (n = 81) women and 49.7% (n = 80) men (Table 1).
By race, 34% (n = 54) were Black, 30% (n = 49) were
Hispanic, and 36% (n = 58) were White. Age at diagnosis
was significantly different between the racial/ethnic
groups (P = 0.01). A trend towards increased prevalence
of thrombocytopenia was observed in Hispanics, how-
ever, these results were not significant. No other differ-
ences in prevalence of cytopenias were noted between
the groups (Table 2). During 590.2 person-years of
follow-up, 52.2% (n = 84) patients died; median survival
was 5.8 years after diagnosis. Unadjusted survival was
not significantly different between Black (6.2 years),
White (3.7), and Hispanic patients (8.6 years; P = 0.28;
Figure 2).Analysis of patients with complete cytogenetics data
Among the patients with results of bone marrow cyto-
genetic studies (n = 135), no significant differences in the
distribution of cytogenetic abnormalities by ethnicity or
prevalence of risk categories by ethnicity were noted
(Table 3). During 458.9 person-years of follow-up, 50.4%
(n = 68) patients died; median survival was 5.5 years after
diagnosis and survival was not significantly different be-
tween Black, White, and Hispanic patients in unadjusted
(P = 0.51) and adjusted analyses (Table 4).Table 2 Frequency of cytopenias for all persons by ethnicity









Anemia 92 (57.1) 30 (55.6) 29 (59.2) 33 (56.9) 0.93
Thrombocytopenia 70 (43.4) 18 (33.3) 27 (55.1) 25 (43.1) 0.08
Neutropenia 18 (11.1) 5 (9.3) 4 (8.2) 9 (15.5) 0.49
n = number of patients.
Figure 2 Kaplan-Meier survival curves by ethnicity.
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to IPSS and IPSS-R risk categories (Table 5). Discrimin-
ation of IPSS-R (Somers’ Dxy = 0.39) was slightly better
than IPSS (Somers’ Dxy = 0.35). Observed median sur-
vival more closely approximated predicted survival with
IPSS than with IPSS-R (Figure 3). For IPSS-R, patients
classified as “Intermediate” risk had a longer median
survival (9.0 years) than patients classified as “Low”
(6.6 years) and “Very Low” risk (8.6 years).Discussion
Our analysis for the first time examines the impact of














Low 65 (48.1) 20 (52.6) 20 (43.5) 25 (49.0)
INT-1 46 (34.1) 15 (39.5) 15 (32.6) 16 (31.4)
INT-2 21 (15.6) 3 (7.9) 9 (19.6) 9 (17.6)
High 3 (2.2) 0 (0) 2 (4.3) 1 (2)
IPSS-R 0.33
Very Low 27 (20) 9 (23.7) 7 (15.2) 11 (21.6)
Low 54 (40) 18 (47.4) 18 (39.1) 18 (35.3)
Intermediate 27 (20) 5 (13.2) 11 (23.9) 11 (21.6)
High 10 (7.4) 4 (10.5) 1 (2.2) 5 (9.8)
Very High 17 (12.6) 2 (5.2) 9 (19.6) 6 (11.7)
n = number of patients, IPSS = International prognostic scoring system,
IPSS-R = Revised international prognostic scoring system.Previous studies have focused on the differences between
WHO morphology from different centers; specifically,
between Asian and European ones. In our cohort,
Hispanics were diagnosed at a younger age when com-
pared with non-Hispanic blacks and whites. Part of this
effect may be related to the demographics of the Bronx;
the Hispanic population tends to be younger than the
non-Hispanic black and white population. Additional
data from other centers would be useful in assessing if
this observation is limited to this center or if in fact
Hispanics do develop MDS at a younger age. Further-
more, prevalence of thrombocytopenia in Hispanics
seemed to be increased but was not statistically signifi-
cant. Neither of these findings resulted in differences in
survival between the ethnic groups, and there were no
differences between distributions by risk score for the
different ethnicities.
The more surprising portion of our analysis was the
observation that the IPSS more accurately predicted sur-
vival than the IPSS-R. This was mediated mostly by better







HR (95% CI) HR (95% CI) HR (95% CI)
Black Reference Reference Reference
White 1.28 (0.70-2.40) 0.92 (0.49-1.78) 0.87 (0.46-1.171)
Hispanic 0.90 (0.47-1.74) 0.72 (0.37-1.42) 0.67 (0.33-1.35)
HR = hazard ratio, CI = confidence interval, IPSS = International prognostic
scoring system, IPSS-R = Revised international prognostic scoring system.
Table 5 Estimated median survival by IPSS and IPSS-R categories
IPSS Survival, observed (y) Survival, reported (y) IPSS-R category Survival, observed (y) Survival, reported (y)
Low 8.6 5.7 Very Low 8.6 8.8
INT-1 4.4 3.5 Low 6.7 5.3
INT-2 0.9 1.2 Intermediate 9.0 3.0
High 0.6 0.4 High 2.7 1.6
Very High 0.8 0.8
IPSS = International prognostic scoring system, IPSS-R = Revised international prognostic scoring system, y = years.
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ingful confidence intervals, which raises the question that
this finding was a statistical anomaly. It is possible that
ethnicity may impact risk stratification in MDS, but how
is not clear. Ethnic cohorts were overall similar to each
other based on clinical criteria used to stratify patients
by IPSS and IPSS-R, and distribution by risk score was
similar as well. A comparison of Somer’s dxy’s by different
ethnic groups could help determine if the IPSS or IPSS-R
performs better for different ethnic groups; unfortunately,
our patient numbers were too small to perform such an
analysis. Larger studies comparing performance of these
systems in multi-ethnic populations may help answer this
question.
Other single center studies have shown that the results
of the IPSS-R, while predictive on a large scale, may not
be predictive in smaller, local cohorts. An analysis of 783
patients from Mayo Clinic showed that IPSS-R karyo-
type categories failed to discriminate between better and
worse prognoses; for example, patients in the “very
good” cateogory had a median survival of 21 months
compared with median survivals of 40 and 24 months
for patients with “good” and “intermediate” cytogenetics,
respectively [16]. The authors found that patients with
monosomal karyotypes had worse survival and suggested
including these patient’s into the “very poor” category.Figure 3 Observed vs. predicted survival by A) IPSS and B) IPSS-R. IPS
International prognostic scoring system, y = years.Our study does have several limitations. MDS as a
disease is often prone to referral bias, as more indolent
forms of the disease are less likely to be referred for
bone marrow biopsy. However, a significant portion of
the identified cohort was noted to have lower grade dis-
ease. How this bias has affected these results remains
unclear. Furthermore, we were unable to access data re-
garding the treatment which these patients received, and
this information could not be included in our analysis.
As a retrospective analysis, we were reliant on accurate
identification of patients’ medical records through ICD-9
codes. We are unsure if ICD-9 codes changed between
the years of 1997 to 2011, but this may have introduced
the possibility of not identifying the records of some pa-
tients with MDS. Furthermore, inaccurate ICD-9 coding
could have limited our ability to identify a larger cohort
of patients.
All patients were drawn from a single center, which
limits the generalizability of these results. Although dif-
ferences were observed in survival by ethnicity, our sam-
ple size was too small to say these were not the result of
chance alone. The SEER database, which includes infor-
mation on tumor type, ethnicity, and survival, would
likely be more definitive in answering questions regard-
ing differences in survival by ethnicity. Finally, although
some observed trends reached statistical significance,S = International prognostic scoring system, IPSS-R = Revised
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ability to detect other differences that actually might
exist. Further analysis in large, prospective, multi-center
cohorts may help better answer whether race has an
impact in the presentation of prognosis of MDS.
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